(Q37621172)

21 August 2017

1 reference

title

Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class (English)

1 reference

21 August 2017

Sharon Walmsley

2

1 reference

ORCID Public Data File 2021

author name string

Troy Grennan

series ordinal

1

1 reference

21 August 2017

publication date

23 October 2009

1 reference

Journal of the International Association of Providers of AIDS Care

21 August 2017

published in

1 reference

21 August 2017

volume

8

1 reference

21 August 2017

issue

6

1 reference

21 August 2017

page(s)

354-363

1 reference

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Class-sparing regimens for initial treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Antiretroviral compounds: mechanisms underlying failure of HAART to eradicate HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Shifting paradigms: the resistance profile of etravirine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 V

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709347373

21 January 2018

Identifiers

DOI

10.1177/1545109709347373

1 reference

21 August 2017

1 reference